Feb 12 (Reuters) – Medical device maker Dexcom beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.
The company also reiterated its 2026 revenue forecast of $5.16 billion to $5.25 billion, the midpoint of which is falls behind analysts’ expectations of $5.24 billion, according to data compiled by LSEG.
In October, CEO Jake Leach had hinted that the company’s 2026 growth forecast may come in “slightly below” estimates.
“2025 was another great year for Dexcom as we significantly expanded access to Dexcom CGM and launched our Dexcom G7 15 Day System,” said CEO Jake Leach. “We look forward to building on this momentum in 2026.”
Growing awareness of diabetes care, wider insurance coverage and a shift toward devices that do not need finger pricks have benefited CGMs such as Dexcom’s Stelo and G7.
Stelo, Dexcom’s over-the-counter CGM for adults who are not on insulin, marks Dexcom’s push into a broader consumer health market, targeting people with type 2 diabetes or those looking to monitor glucose for wellness.
The company is also banking on newer features in its G7 and Stelo CGM apps to increase uptake.
Dexcom reported quarterly revenue of $1.26 billion, up 13% year-over-year, compared with the analysts’ consensus estimate of $1.25 billion.
On an adjusted basis, the company reported a quarterly profit of 68 cents per share, above estimates of 65 cents per share.
(Reporting by Sneha S K in Bengaluru; Editing by Alan Barona)
Comments